Orasis product, CSF-1 is an eye drop currently in clinical development to treat presbyopia. Delivered as a topical solution directly to the eyes, CSF-1 contains a proprietary combination of existing and well-known components with the potential to restore vision in people with presbyopia.

Transforming the lens industry by being able to optimize a lens after implantation. RxSight has developed breakthrough intraocular lens technology for use in cataract and lens replacement surgery. Designed by a Nobel Prize winning scientist, RxSights’s Light Adjustable Lens (RxLAL) utilizes light to enable physicians to make office-based refractive adjustments after it has been implanted in the eye.

Visionary Ventures is a venture capital fund that invests in life sciences and the future of ophthalmology. We are an opportunistic venture fund that invests in early and late stages of a company's growth, from early-stage Series A rounds in clinical trials to late-stage rounds in commercialization. Our target investment range is $500K to $5M.